Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4532990 in NASH
NCT06104319Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of GSK4532990 in Nonalcoholic steatohepatitis (NASH), sponsored by GSK. Started Jan 2024; status: completed.
02
Drugs
GSK4532990
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06104319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104319.